Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding

AIDS Research and Human Retroviruses

Volumn 12, Issue 10, 1996, Pages 911-924

  Binley, James M ^a,b   Ditzel, Henrik J ^a,c   Barbas III, Carlos F ^a   Sullivan, Nancy ^d   Sodroski, Joseph ^d   Parren, Paul W H I ^a   Burton, Dennis R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; PROTEIN SUBUNIT; RECOMBINANT PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ENVELOPE; VIRUS GENE;

EID: 0029957873     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.911     Document Type: Article

References (62)

1. Freed EO, Myers DJ, and Risser R: Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J Virol 1989;63: 4670-4675.
2. Veronese FD, Devico AL, Copeland TD, Oroszlan S, Gallo RC, and Sarngadharan MG: Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 1985;229:1402-1405.
3. Myers G, Korber B, Wain-Hobson S, Jeang K-T, Henderson LE, and Pavlakis GN: Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory, Los Alamos, New Mexico, 1992.
4. Helseth E, Olshevsky U, Furman C, and Sodroski J: Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 1991;65:2119-2123.
5. Poumbourios P, McPhee DA, and Kemp BE: Antibody epitopes sensitive to the state of human immunodeficiency virus type 1 gp41 oligomerization map to a putative alpha-helical region. AIDS Res Hum Retroviruses 1992;8:2055-2062.
6. Thomas DJ, Wall JS, Hainfeld JF, Kaczorek M, Booy FP, Trus BL, Eiserling FA, and Steven AC: gp160, the envelope glycoprotein of human immunodeficiency virus type 1, is a dimer of 125-kilodalton subunits stabilized through interactions between their gp41 domains. J Virol 1991;65:3797-3803.
7. Slepushkin VA, Kornilaeva GV, Andreev SM, Sidorova MV, Petrukhina AO, Matsevich GR, Raduk SV, Grigoriev VB, Makarova TV, Lukashov VV, and Karamov EV: Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein. Virology 1993;194:294-301.
8. Freed EO, Myers DJ, and Risser R: Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci USA 1990;87:4650-4654.
9. Gallaher WR: Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987;50:327-328.
10. Barin F, McLane MF, Allan JS, Lee TH, Groopman JE, and Essex M: Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science 1985;228: 1094-1096.
11. Mathiesen T, Broliden P-A, Rosen J, and Wahren B: Mapping of IgG subclass responses and T-cell epitopes on HIV proteins by synthetic peptides. Immunology 1989;67:453-459.
12. Goudsmit J, Meloen RH, and Brasseur R: Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology 1990;31:327-338.
13. Horal P, Svennerholm B, Jeansson S, Rymo L, Hall WW, and Vahlne A: Continuous epitopes of the human immunodeficiency virus type 1 (HIV-1) tranmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates. J Virol 1991;65:2718-2723.
14. Neurath AR: B cell antigenic mapping of HiV-1 glycoproteins. Chem Immunol 1993;56:34-60.
15. Robinson WE Jr, Kawamura T, Lake D, Masuho Y, Mitchell WM, and Hersh EM: Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp-41 enhance HIV-1 infection in vitro. J Virol 1990; 64:5301-5305.
16. Robinson WE Jr, Gorny MK, Xu J-Y, Mitchell WM, and Zolla-Pazner S: Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 1991;65:4169-4176.
17. Broliden PA, von-Gegerfelt A, Clapham P, Rosen J, Fenyö EM, Wahren B, and Broliden K: Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1992;89:461-465.
18. Buchacher A, Predl R, Tauer C, Purtscher M, Gruber G, Heider R, Steindl F, Trkola A, Jungbauer A, and Katinger H: Human monoclonal antibodies against gp41 and gp120 as potential agents for passive immunization. In: Vaccines '92: Modern Approaches to New Vaccines including Prevention of AIDS (Brown F, Chanock R, Ginsberg HS, and Lerner R, eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1992, pp. 191-194.
19. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67: 6642-6647.
20. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, and Katinger H: Generation of human monoclonal antibodies against HIV-1 proteins: Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-369.
21. Cotropia J, Ugen KE, Lambert D, Ljunggren-Broliden K, Kliks S, Hoxie J, and Weiner DB: Characterization of human monoclonal antibodies to the HIV-1 transmembrane protein. Vaccines 1992; 92:157-163.
22. Gomy MK, Gianakakos V, Sharpe S, and Zolla-Pazner S: Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci USA 1989;86:1624-1628.
23. McClure J and Dickinson E: Human monoclonal antibodies to HIV glycoproteins gp120 and gp41. 6th Intl Conf. on AIDS, San Francisco, California, 1990. S.A.267:148. [Abstract]
24. Pinter A, Honnen WJ, Tilley SA, Bona C, Zaghouani H, Gorny MK, and Zolla-Pazner S: Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol 1989;63:2674-2679.
25. Xu J-Y, Gorny MK, Palker T, Karwowska S, and Zolla-Pazner S: Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991;65: 4832-4838.
26. Laal S and Zolla-Pazner S: Epitopes of HIV-1 glycoproteins recognized by the human immune system. Chem Immunol 1993;56:91-111.
27. Tyler DS, Stanley SD, Zolla-Pazner S, Gorny MK, Shadduck PP, Langlois AJ, Matthews TJ, Bolognesi DP, Palker TJ, and Weinhold KJ: Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990;145:3276-3283.
28. Prigent S, Goossens D, Clerget-Raslain B, Bahraoui E, Roussel M, Tsikas G, Laurent A, Montagnier L, Salmon C, Gluckman J-C, and Rouger P: Production and characterization of human monoclonal antibodies against core protein p25 and transmembrane glycoprotein gp41 of HIV-1. AIDS 1990;4:11-19.
29. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, and Palese P: Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994;68:4031-4034.
30. Trkola A, Pomales AP, Yuan H, Korber B, Maddon PJ, Allaway G, Katinger H, Barbas CF III, Burton DR, Ho DD, and Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
31. D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, and Milman G: Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: An international collaboration. AIDS 1994;8:169-181.
32. Conley AJ, Kessler JA II, Boots LJ, Tung J-S, Arnold BA, Keller PM, Shaw AR, and Emini EA: Neutralization of divergent human immunodeficiency type 1 variants and primary isoaltes by IAM-41-2F5, and anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994;91:3348-3352.
33. Dalgleish AG, Chanh TC, Kennedy RC, Kanda P, Clapham PR, and Weiss RA: Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 1988;165:209-215.
34. Evans DJ, McKeating J, Merdith JM, Burke KL, Katrak K, John A, Ferguson M, Minor PD, Weiss RA, and Almond JW: An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (London) 1989;339:385-340.
35. Sattentau QJ, Zolla-Pazner S, and Poignard P: Epitope exposure on functional, olgiomeric HIV-1 gp41 molecules. Virology 1995;206:713-717.
36. Pincus SH, Messer KG, Schwartz DH, Lewis GK, Graham BS, Blattner WA, and Fisher G: Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 1993;91:1987-1996.
37. Barbas CF III, Kang AS, Lerner RA, and Benkovic SJ: Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc Natl Acad Sci USA 1991;88:7978-7982.
38. Barbas CF III, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, and Burton DR: Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992;89:9339-9343.
39. Barbas CF III, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D, Jones TM, Williamson RA, Pilkington GR, Haigwood NL, Cabezas E, Satterthwait AC, Sanz I, and Burton DR: Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 1993;230:812-823.
40. Burton DR, Barbas CF III, Persson MA, Koenig S, Chanock RM, and Lerner RA: A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10134-10137.
41. Burton DR and Barbas CF III: Human antibodies from combinatorial libraries. Adv Immunol 1994;57:191-280.
42. Ditzel HJ, Binley JM, Moore JP, Sodroski J, Sullivan N, Sawyer LSW, Hendry RM, Yang W-P, Barbas CF III, and Burton DR: Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated using an epitope-masking procedure. J Immunol 1995;154:895-908.
43. Chang S-YP, Bowman BH, Weiss JB, Garcia RE, and White TJ: The origin of HIV-1 isolate HTLV-IIIB. Nature (London) 1993;363:466-469.
44. Barbas CF III and Lerner RA: Combinatorial immunoglobulin libraries on the surface of phage (Phabs): Rapid selection of antigen-specific Fabs. In: Methods: A Companion to Methods in Enzymology (Lemer RA and Burton DR, eds) Academic Press, Orlando, Florida, 1991, pp. 119-124.
45. Persson MA, Caothien RH, and Burton DR: Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci USA 1991;88:2432-2436.
46. Earl PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, Doms RW, and Moss B: Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994;68:3015-3026.
47. Parren PWHI, Fisicaro P, Ditzel HJ, Binley JM, Yang W-P, Barbas III CF, and Burton DR: Manuscript submitted (1996).
48. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, and Winter G: Structural repertoire of the human VH segments. J Mol Biol 1992;227:799-817.
49. Sanz I: Multiple mechanisms participate in the generation of diversity of human H chain CDR3 regions. J Immunol 1991; 147:1720-1729.
50. Myers R, Meiller T, Falkler W Jr, Patel J, and Joseph J: A human monoclonal antibody to a cryptic gp41 epitope on HIV-1 infected cells. In: Abstracts of the 93rd General Meeting of the American Society for Microbiology, Washington, D.C., p. 444. [Abstract T-70].
51. Myers RA: State of Maryland Department of Health and Mental Hygiene. Personal communication.
52. Cao J, Bergeron L, Helseth E, Thali M, Repke H, and Sodroski J: Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 1993;67:2747-2755.
53. Malmborg AC, Michaelsson A, Ohlin M, Jansson B, and Borrebaeck CA: Real time analysis of antibody-antigen reaction kinetics. Scand J Immunol 1992;35:643-650.
54. Karlsson RA, Michaelsson A, and Mattsson L: Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 1991;145:229-240.
55. Vancott TC, Loomis LD, Redfield RR, and Birx DL: Real time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J Immunol 1992;146:163-176.
56. Hanson CV, Crawford-Miksza L, and Sheppard HW: Application of a rapid microplaque assay for determination of human. J Clin Microbiol 1990;28:2030-2034.
57. Nara PL, Hatch WC, Dunlop NM, Robey WG, Arthur LO, Gonda MA, and Fischinger PJ: Simple, rapid, quantitative syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses 1987;3:283-302.
58. Helseth E, Kowalski M, Gabuzda D, Olshevsky U, Haseltine W, and Sodroski J: Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol 1990;64:2416-2420.
59. Wild C, Oas T, McDanal C, Bolognesi D, and Matthews T: A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10537-10541.
60. Chen C-H, Matthews TJ, McDanal CB, Bolognesi DP, and Greenberg ML: A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implication for viral fusion. J Virol 1995;69:3771-3777.
61. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF III, and Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-4828.
62. Collet TA, Roben P, O'Kennedy R, Barbas CF III, Burton DR, and Lemer RA: A binary plasmid system for shuffling combinatorial antibody libraries. Proc Natl Acad Sci USA 1992;89:10026-10030.